What Editas Medicine, Inc. told the SEC could break it.

Editas has no product revenue and expects continuing, increasing operating losses; it relies on collaboration payments (BMS, Vertex), royalty monetization (DRI), and equity raises, and owes contingent 'Success Payments' (cash/stock/notes) to licensors.

“To date, we have not generated any revenue from product sales and we do not expect to generate any revenue from product sales for the foreseeable future.”

Any future Editas product would depend on third-party payer coverage and adequate reimbursement; patients are unlikely to use products without it, and U.S. drug-pricing reforms add uncertainty.

“patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use any product candidates we may develop unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of such product candidates.”